论文部分内容阅读
α1 胸腺肽是生物反应的修饰因子 ,临床上已被应用于慢性乙肝病人的治疗。我们建立了一个新的动物模型及相应条件 ,通过测定乙肝病毒的表面抗体的生成量来估价胸腺肽活性。证明了化学合成的α1 胸腺肽恢复由 5 - Fu诱发的免疫抑制中 T细胞中介的抗体产量。发现 α1 胸腺肽在 30 ug/ kg的低剂量下显示活性。流式细胞仪分析表明 ,α1 胸腺肽在此剂量加快胸腺细胞的成熟 ,是根据 CD4 - CD8-胸腺细胞上 Hh信号的 Sm o分子的表达确定的 ,- Sm o是增生反应的潜在阴性调节者。本篇研究提供了在乙肝病毒感染中 T细胞介导的免疫应答恢复的新模型
α1 thymosin is a biological response modifier, has been clinically used in the treatment of chronic hepatitis B patients. We have established a new animal model and the corresponding conditions, by measuring the formation of hepatitis B virus surface antibodies to assess the thymosin activity. It was demonstrated that chemically synthesized α1 thymosin restored the antibody production mediated by 5 - Fu in immunosuppressed T cells. The α1 thymosin was found to show activity at low doses of 30 μg / kg. Flow cytometry analysis showed that α1 thymosin at this dose accelerated thymocyte maturation based on the expression of Sm o molecules on the Hh signal on CD4 - CD8 - thymocytes, and - Sm o was a potential negative regulator of proliferative responses. This study provides a new model of T cell-mediated immune response recovery in hepatitis B virus infection